<DOC>
	<DOCNO>NCT01287546</DOCNO>
	<brief_summary>The objective study determine recommend Phase 2 dose range LY2875358 may safely administer participant advanced cancer . In Part A Part A2 study , escalate dos LY2875358 monotherapy combination erlotinib evaluate safety tolerability , respectively . Part B dose-confirmation segment LY2875358 therapy 5 different type cancer : nonsquamous non-small cell lung cancer ( NSCLC ) , castrate resistant prostate cancer ( CRPC ) bone metastasis , renal cell carcinoma ( RCC ) , hepatocellular carcinoma ( HCC ) , uveal melanoma liver metastasis , LY2875358 combination trametinib participant uveal melanoma liver metastasis .</brief_summary>
	<brief_title>A Study LY2875358 Participants With Advanced Cancer</brief_title>
	<detailed_description>Protocol amendment ( November , 2013 ) expand Part B study LY2875358 combination trametinib participant uveal melanoma liver metastasis .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Part A : Have histological cytological evidence cancer ( solid tumor , lymphoma , multiple myeloma ) advance and/or metastatic appropriate candidate experimental therapy Part A2 : Histologic cytologic diagnosis advance Non Small Cell Lung Cancer ( NSCLC ) , Stage IIIB malignant pleural effusion Stage IV , complete least 1 prior systemic regimen , eligible erlotinib therapy . Part B : Candidate experimental therapy standard therapy use noneligible standard therapy . Histological cytological evidence 1 5 tumor type : Castrateresistant prostate cancer ( CRPC ) bone metastasis : Progressive Disease set castrate level testosterone Renal Cell Carcinoma ( RCC ) : Histologic diagnosis either clearcell papillary RCC ( metastatic unresectable , bilateral , multifocal , unresectable RCC localize kidney ) . NSCLC : Histologic cytologic diagnosis advance NSCLC , Stage IIIB malignant pleural effusion Stage IV Hepatocellular Carcinoma ( HCC ) Histologic cytologic diagnosis hepatocellular carcinoma Uveal Melanoma liver metastasis Part A : Have presence measurable nonmeasurable disease define RECIST v1.1 ( Eisenhauer et al . 2009 ) Revised Response Criteria Malignant Lymphoma ( Cheson et al . 2007 ) measureable disease multiple myeloma . Part A2 &amp; B ( RCC , NSCLC , HCC , uveal melanoma ) : Have measurable disease define RECIST v1.1 . Give write informed consent prior studyspecific procedure . Adequate organ function . Performance status less equal 2 ECOG scale . Discontinued previous cancer therapy , agent receive regulatory approval , least 21 day recover acute effect therapy . Must discontinue mitomycinC nitrosourea therapy least 42 day . Reliable available duration study willing follow study procedure . Males female ( reproductive potential ) : Use medically approve contraceptive precaution study 4 month follow last dose study drug . Females ( childbearing potential ) : Have negative serum pregnancy test first dose study drug breastfeeding . Estimated life expectancy permit participant complete 8 week treatment . Serious preexist medical condition Symptomatic central nervous system malignancy metastasis ( screen require ) . Acute chronic leukemia . Active infection include HIV , hepatitis A , B C Have second primary malignancy may affect interpretation result . Have receive liver transplant , liver cirrhosis ChildPugh Stage B C. Patients active alcohol abuse , determine treat investigator . Part A2 : Unable swallow tablet . Intolerant therapy erlotinib . Concomitant treatment cytochrome P450 3A ( CYP3A ) modulators . Must receive treatment modulators within 14 day study treatment . Have history New York Heart Association class â‰¥3 , unstable angina , myocardial infarction 6 month prior study drug QTc great 470 msec . Received previous treatment cMET experimental therapeutic . Part B Expansion Cohort 1 ( CRPC ) : 1 . Increasing use daily dos opioid analgesic within 28 day prior enrollment study . 2 . Neuroendocrine prostate cancer . 3 . Patients solitary bone metastasis irradiate eligible . Part B Expansion Cohort 6 ( LY2875358 plus trametinib participant uveal melanoma liver metastasis ) : Contraindications trametinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>